

AMENDMENTS TO THE CLAIMS

1. **(Original)** An isolated, purified or recombinant complex, comprising a Cbl-b polypeptide and a POSH polypeptide.
2. **(Cancelled)**
3. **(Currently Amended)** A method of identifying an antiviral agent, comprising identifying a test agent that disrupts a complex of claim 1any of claims 1-2.
4. **(Currently Amended)** The complex of claim 1any of claims 1-2, wherein the Cbl-b polypeptide is a human Cbl-b polypeptide.
5. **(Currently Amended)** The complex of claim 1any of claims 1-2, wherein the POSH polypeptide is a human POSH polypeptide.
6. **(Currently Amended)** A method of identifying an agent that modulates an activity of a Cbl-b polypeptide and a POSH polypeptide, comprising identifying an agent that disrupts a complex of claim 1any one of claims 1-2, wherein an agent that disrupts a complex of claim 1any one of claims 1-2 is an agent that modulates an activity of the Cbl-b polypeptide or the POSH polypeptide.
7. **(Original)** A method of identifying an antiviral agent, comprising:
 - a) identifying a test agent that disrupts a complex comprising a Cbl-b polypeptide and a Cbl-b-AP polypeptide; and
 - b) evaluating the effect of the test agent on a function of a virus, wherein an agent that inhibits a pro-infective or pro-replicative function of a virus is an antiviral agent.
8. **(Original)** The method of claim 7, wherein the Cbl-b-AP is POSH.
9. **(Original)** The method of claim 7, wherein the virus is an envelope virus.

10. **(Original)** The method of claim 9, wherein the virus is a Human Immunodeficiency Virus.

11. **(Original)** The method of claim 7, wherein evaluating the effect of the test agent on a function of the virus comprises evaluating the effect of the test agent on the budding, release, infectivity, or reverse transcriptase activity of the virus or a virus-like particle.

12. **(Cancelled)**

13. **(Currently Amended)** The method of claim 7[[12]], wherein said agent is selected from among: an siRNA construct, an antisense construct, an antibody, a polypeptide, and a small molecule.

14-24. **(Cancelled)**

25. **(Original)** A method of identifying an antiviral agent, comprising:
a) identifying a test agent that inhibits an activity of or expression of a Cbl-b polypeptide; and
b) evaluating an effect of the test agent on a function of a virus.

26. **(Cancelled)**

27. **(Currently Amended)** The method of claim 25 [[or 26]], wherein the virus is an envelope virus.

28. **(Currently Amended)** The method of claim 25 [[or 26]], wherein the virus is a Human Immunodeficiency Virus.

29. **(Currently Amended)** The method of claim 25 [[or 26]], wherein evaluating the effect of the test agent on a function of the virus comprises evaluating the effect of the test agent on the budding, release, infectivity, or reverse transcriptase activity of the virus or a virus-like particle.

30. **(Currently Amended)** The method of claim 25 [[or 26]], wherein the test agent is selected from among: an siRNA construct, an antisense construct, an antibody, a polypeptide, and a small molecule.

31. **(Original)** The method of claim 30, wherein the test agent is an siRNA construct that inhibits the expression of Cbl-b and is selected from among SEQ ID NOS: 59-64.

32-46. **(Cancelled)**

47. **(Currently Amended)** The method of claim 25[[46]], wherein the agent inhibits the ubiquitin ligase activity of the Cbl-b polypeptide.

48-49. **(Cancelled)**

50. **(Currently Amended)** The method of claim 25, wherein the An isolated Cbl-b polypeptide, comprising comprises the amino acid sequence depicted in SEQ ID NO: 45.

51-52. **(Cancelled)**

53. **(Currently Amended)** The method of claim 25, wherein the An isolated Cbl-b polypeptide, comprising comprises the amino acid sequence depicted in SEQ ID NO: 46.

54-63. **(Cancelled)**